Total Payments
$106,791
2024 Payments
$1,525
Companies
13
Transactions
102
Payment Breakdown by Category
Consulting$80,112 (75.0%)
Other$24,294 (22.7%)
Travel$1,647 (1.5%)
Food & Beverage$558.42 (0.5%)
Education$180.00 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $80,112 | 74 | 75.0% |
| Honoraria | $24,294 | 7 | 22.7% |
| Travel and Lodging | $1,647 | 7 | 1.5% |
| Food and Beverage | $558.42 | 8 | 0.5% |
| Education | $180.00 | 6 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Horizon Therapeutics plc | $20,306 | 14 | $0 (2022) |
| Travere Therapeutics, Inc. | $18,075 | 28 | $0 (2023) |
| Retrophin, Inc. | $17,963 | 17 | $0 (2019) |
| BioMarin Pharmaceutical Inc. | $12,900 | 3 | $0 (2019) |
| Amicus Therapeutics, Inc. | $12,308 | 15 | $0 (2023) |
| Ultragenyx Pharmaceutical Inc. | $8,980 | 10 | $0 (2021) |
| ModernaTX, Inc. | $6,300 | 2 | $0 (2022) |
| Horizon Pharma plc | $5,968 | 7 | $0 (2018) |
| UCB SA | $2,511 | 2 | $0 (2024) |
| GlaxoSmithKline, LLC. | $500.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,525 | 3 | UCB SA ($900.00) |
| 2023 | $9,794 | 5 | Travere Therapeutics, Inc. ($6,650) |
| 2022 | $15,213 | 11 | ModernaTX, Inc. ($6,300) |
| 2021 | $14,534 | 12 | Horizon Therapeutics plc ($9,494) |
| 2020 | $27,028 | 34 | Ultragenyx Pharmaceutical Inc. ($8,890) |
| 2019 | $14,972 | 21 | Retrophin, Inc. ($11,763) |
| 2018 | $8,317 | 8 | Retrophin, Inc. ($6,200) |
| 2017 | $15,409 | 8 | BioMarin Pharmaceutical Inc. ($8,775) |
All Payment Transactions
102 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/01/2024 | Mirum Pharmaceuticals, Inc. | Cholbam (Drug) | Consulting Fee | Cash or cash equivalent | $225.00 | General |
| Category: Hepatology | ||||||
| 01/18/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 01/05/2024 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 11/10/2023 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $1,611.00 | General |
| 08/08/2023 | Amicus Therapeutics, Inc. | POMBILITI (Drug), OPFOLDA | Consulting Fee | Cash or cash equivalent | $733.00 | General |
| Category: POMPE DISEASE | ||||||
| 06/23/2023 | Amicus Therapeutics, Inc. | POMBILITI (Drug), OPFOLDA | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: POMPE DISEASE | ||||||
| 03/28/2023 | Travere Therapeutics, Inc. | Cholbam (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: Hepatology | ||||||
| 01/17/2023 | Travere Therapeutics, Inc. | Cholbam (Drug) | Consulting Fee | Cash or cash equivalent | $6,200.00 | General |
| Category: Hepatology | ||||||
| 12/13/2022 | Travere Therapeutics, Inc. | Cholbam (Drug) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: Hepatology | ||||||
| 11/28/2022 | Travere Therapeutics, Inc. | Cholbam (Drug) | Consulting Fee | Cash or cash equivalent | $225.00 | General |
| Category: Hepatology | ||||||
| 09/20/2022 | Travere Therapeutics, Inc. | Cholbam (Drug) | Consulting Fee | Cash or cash equivalent | $225.00 | General |
| Category: Hepatology | ||||||
| 08/09/2022 | Amicus Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 08/09/2022 | Amicus Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 06/23/2022 | Horizon Therapeutics plc | RAVICTI (Drug) | Honoraria | Cash or cash equivalent | $5,250.00 | General |
| Category: RAVICTI | ||||||
| 06/22/2022 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 06/22/2022 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 04/05/2022 | Travere Therapeutics, Inc. | Cholbam (Drug) | Consulting Fee | Cash or cash equivalent | $112.50 | General |
| Category: Hepatology | ||||||
| 02/08/2022 | Travere Therapeutics, Inc. | Cholbam (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: Hepatology | ||||||
| 01/05/2022 | Travere Therapeutics, Inc. | Cholbam (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: Hepatology | ||||||
| 11/15/2021 | Travere Therapeutics, Inc. | Cholbam (Drug) | Consulting Fee | Cash or cash equivalent | $112.50 | General |
| Category: Hepatology | ||||||
| 11/04/2021 | Horizon Therapeutics plc | RAVICTI (Drug) | Honoraria | Cash or cash equivalent | $3,500.00 | General |
| Category: RAVICTI | ||||||
| 10/09/2021 | Travere Therapeutics, Inc. | Cholbam (Drug) | Consulting Fee | Cash or cash equivalent | $1,462.50 | General |
| Category: Hepatology | ||||||
| 09/21/2021 | Amicus Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,366.66 | General |
| 09/02/2021 | Ultragenyx Pharmaceutical Inc. | Dojolvi (Drug) | Education | In-kind items and services | $30.00 | General |
| Category: Oral nutritional supplements | ||||||
| 09/02/2021 | Ultragenyx Pharmaceutical Inc. | — | Education | In-kind items and services | $30.00 | General |
About Dr. Gregory Enns, M.D
Dr. Gregory Enns, M.D is a Medical Biochemical Genetics healthcare provider based in Palo Alto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508961897.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Enns, M.D has received a total of $106,791 in payments from pharmaceutical and medical device companies, with $1,525 received in 2024. These payments were reported across 102 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($80,112).
Ad
Practice Information
- Specialty Medical Biochemical Genetics
- Other Specialties Clinical Genetics (M.D.), Clinical Biochemical Genetics
- Location Palo Alto, CA
- Active Since 09/13/2006
- Last Updated 04/09/2024
- Taxonomy Code 207SG0207X
- Entity Type Individual
- NPI Number 1508961897
Products in Payments
- RAVICTI (Drug) $26,255
- (820) Cholbam (Drug) $22,763
- Cholbam (Drug) $10,988
- DOJOLVI (Drug) $8,800
- BMN 165 (Biological) $8,775
- Kuvan (Drug) $2,198
- BMN 165 (Drug) $1,928
- POMBILITI (Drug) $1,533
- (815) Thiola (Drug) $1,500
- Dojolvi (Drug) $60.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.